The latest announcement is out from Oxurion NV ( (GB:0G99) ).
Oxurion NV has announced an extension to its financing program through a third amendment to its convertible bond subscription agreement with Atlas Special Opportunities, LLC. This amendment allows Oxurion to issue convertible bonds under lighter conditions until December 2025, with the overall program extended to March 2026, ensuring a standardized maturity structure for all bonds. The changes aim to provide Oxurion with greater financial flexibility, potentially strengthening its position in the ophthalmic therapy market.
More about Oxurion NV
Oxurion NV is a biotechnology company based in Leuven, Belgium, specializing in the development of next-generation ophthalmic therapies for the treatment of retinal diseases.
Average Trading Volume: 3
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: €727.7K
For an in-depth examination of 0G99 stock, go to TipRanks’ Stock Analysis page.